ResMed Slashes 7.2%: The Astral Anomaly and the Earnings Trap

Summary
• ResMed Inc. (RMD) closed sharply lower at $207.09, marking a -7.23% intraday decline.

• Fiscal Q4 EPS beat consensus at $2.95, but revenue narrowly missed at $1.46 billion.

• First-ever annual guidance projects only 5-7% core revenue growth for FY27, signaling a structural slowdown.

• A $75 million headwind from the Astral ventilator field safety action heavily weighs on near-term sentiment.

Despite a solid earnings beat, the market punished ResMed shares in a volatile session that saw prices oscillate between a low of $202.00 and a high of $215.50. Investors are currently digesting a complex narrative where profitability outperformed expectations, yet conservative forward guidance and significant product-specific headwinds have triggered a massive reassessment of the stock's near-term trajectory.
Astral Safety Action and Conservative Guidance Trigger Sell-Off
The precipitous drop in ResMed shares was not driven by a collapse in current quarter performance, but rather by a stark pivot in forward-looking sentiment. While non-GAAP earnings of $2.95 per share exceeded the consensus estimate of $2.89, the revenue figure of $1.46 billion just fell short of the $1.47 billion expectation. More critically, management issued its first formal annual guidance, projecting fiscal 2027 core revenue growth of merely 5% to 7%, a significant deceleration from the 8% constant-currency growth achieved in fiscal 2026. This slowdown is largely attributed to a $75 million revenue headwind stemming from a field safety corrective action on the Astral ventilator product range, which will result in a complete sales halt for the line through fiscal 2027. Additionally, the anticipated dilution from the $340 million acquisition of Noctrix Health and the divestiture of MatrixCare software further clouded the earnings outlook, prompting analysts at RBC Capital and Wells Fargo to immediately lower their price targets.

Health Care Equipment Divergence: Medtronic Stability Contrasts with ResMed Volatility
The broader Health Care Equipment & Supplies sector remains relatively stable, highlighting that ResMed’s decline is strictly idiosyncratic rather than systemic. Sector leader Medtronic (MDT) posted a modest intraday gain of 0.18%, underscoring a divergence in investor confidence between industry giants. While the sector faces general macroeconomic headwinds such as inflation and hospital spending pressures, Medtronic’s steady performance indicates resilience. In contrast, ResMed’s double-digit percentage drop serves as a stark reminder that company-specific operational risks, particularly those involving regulatory safety actions and product line suspensions, can severely decouple a stock from its sector peers, even when broader market indices like the S&P 500 and Nasdaq remain flat or post modest gains.

Defensive Put Strategies and Volatility Plays Amid Technical Overshoot
Technical indicators present a conflicting picture that demands caution. The stock is currently trading below its 200-day moving average of $231.05 and the 100-day average of $209.31, confirming a bearish medium-term trend. However, the RSI sits at 73.55, signaling overbought conditions on a short-term basis, while the MACD histogram remains positive at 2.55, suggesting lingering bullish momentum despite the price drop. The 30-day moving average at $205.23 offers immediate support.

• 200-day MA: $231.05 (below)

• RSI: 73.55 (overbought)

• MACD Histogram: 2.55 (positive momentum)

• Support Level: $205.23 (30-day MA)

From a tactical perspective, the market's reaction to the Astral headwind suggests that downside protection is paramount. Traders should note the performance of leveraged ETFs; the Direxion Daily S&P 500 Bull 3X ETF (SPXL) rose 1.78% and ProShares UltraPro S&P500 (UPRO) gained 1.76%, indicating that the broader market is ignoring ResMed's pain. For ResMed specifically, the options chain reveals significant interest in downside protection. We identify two high-conviction options based on high leverage, moderate delta, and strong liquidity metrics.

• RMD20260821C210: Call Option, Strike $210, Expiration 2026-08-21. IV: 29.91%, Leverage: 44.64x, Delta: 0.49, Theta: -0.40, Gamma: 0.03, Turnover: $27,564. Delta indicates moderate price sensitivity. Theta reflects high daily time decay. Gamma shows strong responsiveness to price changes.

This contract stands out for its high liquidity and significant leverage ratio relative to its delta, offering aggressive bulls a leveraged play on a potential bounce above the $210 resistance level. The high turnover ensures easy entry and exit.

• RMD20260918P200: Put Option, Strike $200, Expiration 2026-09-18. IV: 35.00%, Leverage: 36.98x, Delta: -0.32, Theta: -0.04, Gamma: 0.01, Turnover: $46,824. Delta suggests moderate downside sensitivity. Theta indicates lower daily decay. Gamma reflects moderate price movement sensitivity.

This contract offers superior liquidity with the highest turnover in the chain and a delta that provides substantial downside exposure without the extreme cost of deep out-of-the-money puts. It is ideal for hedging against further erosion toward the $200 support level.

Options Payoff Calculation Primer: For this payoff estimation, we assume a 5% downside scenario from current price ($207.09) where for Call Option Payoff = max(0, ST - K) where ST is projected price and K is strike price and Put Option Payoff = max(0, K - ST) where ST is projected price and K is strike price. This projection helps evaluate option contracts' potential returns under a bearish move scenario.

If $205 breaks, RMD20260918P200 offers high-probability downside protection.

Hold Cash: Wait for Clarity on Astral Resolution
The current volatility in ResMed is a direct reflection of the market pricing in tangible operational risks rather than speculative sentiment. The Astral ventilator suspension and the conservative 5-7% growth guide represent a fundamental shift in the company's near-term revenue engine, making immediate buying highly risky. Investors should adopt a wait-and-see approach, monitoring the execution of the MatrixCare divestiture and the integration of Noctrix for signs of margin recovery. The broader market stability, highlighted by Medtronic (MDT) maintaining a +0.18% gain, suggests that capital is rotating toward safer havens. Watch for a sustained break below $205 or any regulatory updates regarding the Astral safety action to determine the next directional move.